The normal HCT trial re-revisited: what were the actual findings?
作者信息
Besarab Anatole, Bolton W Kline, Nissenson Allen R, Schwab Steven J
出版信息
Kidney Int. 2012 Jul;82(2):242; author reply 242-3. doi: 10.1038/ki.2012.204.
PMID:22743566
Abstract
摘要
相似文献
1
The normal HCT trial re-revisited: what were the actual findings?
Kidney Int. 2012 Jul;82(2):242; author reply 242-3. doi: 10.1038/ki.2012.204.
2
A physician's perseverance uncovers problems in a key nephrology study.一位医生的坚持揭示了一项关键肾脏病学研究中的问题。
Kidney Int. 2012 Jul;82(2):135-7. doi: 10.1038/ki.2012.122.
3
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.在正常红细胞压积试验中，针对更高的血红蛋白水平并没有改善与健康相关的生活质量。
Kidney Int. 2012 Jul;82(2):235-41. doi: 10.1038/ki.2012.76. Epub 2012 Mar 21.
4
Use of erythropoietins in patients with renal transplants.促红细胞生成素在肾移植患者中的应用。
BMJ. 2009 Oct 23;339:b3825. doi: 10.1136/bmj.b3825.
5
Full results on risks of epoetin emerge 14 years after major dialysis study.
BMJ. 2012 May 22;344:e3535. doi: 10.1136/bmj.e3535.
6
Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?TRIAL 研究对贫血管理的启示：阿法依泊汀治疗能否减少透析患者心血管事件？
Curr Opin Nephrol Hypertens. 2010 Nov;19(6):567-72. doi: 10.1097/MNH.0b013e32833c3cc7.
7
Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?促红细胞生成素刺激剂与阿法依泊汀再探讨：真正相关的是什么？
Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. doi: 10.2215/CJN.02300508. Epub 2008 Jun 25.
8
Darbepoetin alfa and chronic kidney disease.达比泊汀α与慢性肾脏病
N Engl J Med. 2010 Feb 18;362(7):654; author reply 655.
9
The FDA black box for EPO: what should nephrologists do?美国食品药品监督管理局针对促红细胞生成素的黑框警告：肾病学家该怎么做？
Nephrol News Issues. 2007 May;21(6):55-6, 58-9.
10
Does TREAT give the boot to ESAs in the treatment of CKD anemia?在慢性肾脏病贫血的治疗中，TREAT是否会淘汰促红细胞生成素类药物？
J Am Soc Nephrol. 2010 Jan;21(1):2-6. doi: 10.1681/ASN.2009111127. Epub 2009 Dec 24.
Zotero 插件